Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

TAGRAXOFUSP-ERZS for Acute myeloid leukaemia: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 30 adverse event reports in the FDA FAERS database where TAGRAXOFUSP-ERZS was used for Acute myeloid leukaemia.

Most Reported Side Effects for TAGRAXOFUSP-ERZS

Side Effect Reports % Deaths Hosp.
Capillary leak syndrome 110 25.1% 35 55
Pyrexia 45 10.3% 10 17
Death 36 8.2% 36 3
Disease progression 33 7.5% 16 6
Thrombocytopenia 26 5.9% 7 10
Blood albumin decreased 24 5.5% 2 8
Acute kidney injury 23 5.3% 8 11
Off label use 23 5.3% 12 6
Weight increased 22 5.0% 8 6
Transaminases increased 21 4.8% 6 6
Tumour lysis syndrome 21 4.8% 9 3
Sepsis 19 4.3% 9 14
Liver function test increased 18 4.1% 3 5
Hypoalbuminaemia 17 3.9% 2 7
Hypotension 17 3.9% 7 10

Other Indications for TAGRAXOFUSP-ERZS

Blastic plasmacytoid dendritic cell neoplasia (273) Product used for unknown indication (109)

Other Drugs Used for Acute myeloid leukaemia

VENETOCLAX (19,774) AZACITIDINE (9,065) CYTARABINE (8,295) IDARUBICIN (2,427) DAUNORUBICIN (2,423) ENASIDENIB (2,220) GILTERITINIB (1,963) FLUDARABINE (1,927) MIDOSTAURIN (1,653) DECITABINE (1,400)

Related Pages

TAGRAXOFUSP-ERZS Full Profile All Acute myeloid leukaemia Drugs TAGRAXOFUSP-ERZS Demographics TAGRAXOFUSP-ERZS Timeline